Venous thromboembolism (VTE) is a potentially fatal vascular disease that affects more than 170,000 patients in the USA every year. All hospitalized patients are at an increased risk of developing VTE and subsequent pulmonary embolus.
There is growing literature concentrating on the cost-effectiveness of preventing VTE occurring. So far recommendations have been conflicting and research has not explored the use of VTE prophylaxis in low-risk patient groups.
Comparisons between low-molecular-weight heparins (LMWH) and unfractionated heparins have revealed that LMWHs are superior not only in action but also in cost-effectiveness.
In elective surgery, patients who require long-term anticoagulation bridging therapy with LMWH at home have shown comparable safety and efficacy and the method is far less costly than inpatient bridging therapy with unfractionated heparin.
AndersonFA, WheelerHB, GoldbergRJ. A population-based perspective on the hospital incidence and age-fatality rates of deep vein thrombosis and pulmonary embolism. The Worrchester DVT Study. Arch Intern Med1991; 151: 933–8.
2.
HeparinHirsh J.N Engl J Med1991; 324: 1565–74
3.
GeertsWH, HeitJA, ClagettCP. Prevention of venous thromboembolism. Chest2001; 119: 132S–75S
4.
GoldhaberSZ, DunnK, MacDougallRC. New onset of thromboembolism among hospitalised patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest2000; 118: 1680–4.
5.
SalzmanEW, DaviesGC. Prophylaxis of venous thromboembolism: analysis of cost effectiveness. Ann Surg1980; 191: 207–18.
6.
OsterG, TudenRL, ColditzGA. Prevention of venous thromboembolism after general surgery. Cost-effectiveness analysis of alternative approaches to prophylaxis. Am J Med1987; 82: 889–99.
7.
OsterG, TudenRL, ColditzGA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopaedic surgery. JAMA1987; 257: 203–8.
8.
BergqvistD, JendtegS, LindgrenB, MatzschT, PerssonU. The economics of general thromboembolic prophylaxis. World J Surg1988; 12: 349–55.
9.
BergqvistD, MatzschT, JendtegS, LindgrenB, PerssonU. The cost-effectiveness of prevention of post-operative thromboembolism. Acta Chir Scand Suppl1990; 556: 36–41.
10.
HullRD, HirshJ, SackettDL, StoddartGL. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J1982; 127: 990–5.
11.
GouldMK, DembitzerAD, SandersGD, GarberAM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med1999; 130: 789–99.
12.
MaxwellGL, MyersER, Clarke-PearsonDL. Cost-effectiveness of deep venous thrombosis prophylaxis in gynaecologic oncology surgery. Obstet Gynecol2000; 95: 206–14.
13.
DaintyL, MaxwellGL, Clarke-PearsonDL, MyersER. Cost-effectiveness of combination thromboembolism prophylaxis in gynaecologic oncology surgery. Gynecol Oncol2004; 93: 366–73.
14.
HolmerE, MattssonC, NilssonS. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res1982; 25: 475–85.
15.
YoungE, PrinsMH, LevineMN, HirshJ. Heparin binding of plasma proteins, and important mechanism for heparin resistance. Thromb Haemost1992; 67: 639–43.
16.
KoopmanMM, PrandoniP, PiovellaF. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med1996; 334: 682–7.
17.
AmorosiSL, TsilimingrasK, ThompsonD, FanikosJ, WeinsteinMC, GoldhaberSZ. Cost analysis of ‘bridging therapy’ with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. Am J Cardiol2004; 93: 509–11.
18.
HeitJA. Perioerative management of the chronically anticoagulated patient. J Thromb Thrombolysis2001; 12: 81–7.
SpandorferJM, LynchS, WeitzHH, FertelS, MerliGJ. Use of enoxeparin for the chronically antiicoagulated patient before and after procedures. Am J Cardiol1999; 84: 478–80.
21.
TinmouthAH, MorrowBH, CruickshankMK, MoorePM, KovacsMJ. Dalteparin as periproedure antic-oagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother2001; 35: 669–74.
22.
SpyropoulosAC, FrostFJ, HurleyJS, RobertsM. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perio-perative bridging in patients receiving long-term oral anticoagulant therapy. Chest2004; 125: 1642–50.
23.
McGarryLJ, ThompsonD, WeinsteinMC, GoldhaberSZ. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manage Care2004; 10: 632–42.
